ARCTURUS THERAPEUTICS
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 16 Feb 2024)
What this means for you
Registered since 10 Apr 2018. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 10 Apr 2028: the §8 & §9 renewal).
Record
- Serial number
- 86563776
- Registration number
- 5443638
- Mark type
- Word mark
- Filed
- 13 Mar 2015
- Published for opposition
- 19 Jan 2016
- Registered
- 10 Apr 2018
- Next maintenance filing
- §8 & §9 renewal, due by 10 Apr 2028 (grace period to 10 Oct 2028)
- Attorney of record
- Kevin M. Bovard
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, a lipid-enabled drug delivery system for RNA medicines comprising small interfering RNA, messenger RNA, antisense and microRNA oligotherapeutic agents to enable the targeting of any gene in the human genome
- Class 042 — Scientific and technological services: Scientific and medical research
Owner
- Arcturus Therapeutics, Inc., San Diego, CA, US
- Arcturus Therapeutics, Inc., San Diego, CA, US
- Arcturus Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 16 Feb 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 16 Feb 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 15 Feb 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 29 Aug 2023 — TEAS SECTION 8 & 15 RECEIVED
- 10 Apr 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 10 Apr 2018 — REGISTERED-PRINCIPAL REGISTER
- 08 Mar 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 07 Mar 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 06 Mar 2018 — STATEMENT OF USE PROCESSING COMPLETE
- 12 Feb 2018 — USE AMENDMENT FILED
- 28 Feb 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Feb 2018 — TEAS STATEMENT OF USE RECEIVED
- 02 Sept 2017 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Aug 2017 — SOU EXTENSION 3 GRANTED
- 31 Aug 2017 — SOU EXTENSION 3 FILED